{"id":6000,"date":"2023-06-08T20:22:48","date_gmt":"2023-06-08T20:22:48","guid":{"rendered":"https:\/\/founderlodge.com\/latest-news\/?p=6000"},"modified":"2023-06-08T20:22:50","modified_gmt":"2023-06-08T20:22:50","slug":"aavantgarde-bio-raises-65-million-in-series-a-funding","status":"publish","type":"post","link":"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/","title":{"rendered":"AAVantgarde Bio Raises $65 Million in Series A Funding."},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-87.png\" alt=\"\" class=\"wp-image-6001\" width=\"89\" height=\"87\" \/><\/figure>\n\n\n\n<p>Milan, Lombardy, Italy &#8211; <a href=\"https:\/\/www.aavantgardebio.com\/en\/homepage\/\">AAVantgarde Bio<\/a>, a clinical-stage biotechnology company based in Italy, has successfully raised $65,333,745 in its Series A funding round. The investment was led by renowned venture capital firms <a href=\"https:\/\/atlasventure.com\/\">Atlas Venture<\/a> and <a href=\"https:\/\/sofinnovapartners.com\/\">Sofinnova Partners<\/a>, along with participation from<a href=\"https:\/\/forbion.com\/en\/\"> Forbion<\/a> and <a href=\"https:\/\/www.longwoodfund.com\/\">Longwood Fund<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"541\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-88-1024x541.png\" alt=\"\" class=\"wp-image-6002\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-88-1024x541.png 1024w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-88-300x158.png 300w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-88-768x406.png 768w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-88.png 1068w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>AAVantgarde Bio has established itself as an international leader in the field of biotechnology research. The company has developed two proprietary Adeno-Associated Viral (AAV) vector platforms, aiming to overcome the gene therapy cargo capacity limitations associated with traditional AAV vectors.<\/p>\n\n\n\n<p>The groundbreaking platform developed by AAVantgarde Bio is currently undergoing clinical validation for two Inherited Retinal Diseases: Usher1B and Stargardt disease. By addressing the gene therapy cargo capacity limitations of AAV vectors, AAVantgarde Bio&#8217;s platform holds the potential to revolutionize treatment options in a wide range of disease areas.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"472\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-89-1024x472.png\" alt=\"\" class=\"wp-image-6003\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-89-1024x472.png 1024w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-89-300x138.png 300w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-89-768x354.png 768w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-89.png 1123w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Dr. <a href=\"https:\/\/www.linkedin.com\/in\/natalia-misciattelli-mocenigo-soranzo-7062691\/\">Natalia Misciattelli Mocenigo Soranzo<\/a>, Founder of AAVantgarde Bio, expressed her gratitude for the support received from investors and shared her excitement about the company&#8217;s future prospects. She stated, &#8220;We are thrilled to have secured this significant funding, which will propel our mission of advancing gene therapy and bringing hope to patients worldwide. This investment will allow us to continue pushing the boundaries of biotechnology and expanding our platform to address a multitude of genetic diseases.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Milan, Lombardy, Italy &#8211; AAVantgarde Bio, a clinical-stage biotechnology company based in Italy, has successfully raised $65,333,745 in its Series A funding round. The investment was led by renowned venture capital firms Atlas Venture and Sofinnova Partners, along with participation from Forbion and Longwood Fund. AAVantgarde Bio has established itself as an international leader in [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":6004,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"categories":[2],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.2.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AAVantgarde Bio Raises $65 Million in Series A Funding.<\/title>\n<meta name=\"description\" content=\"Milan, Lombardy, Italy - AAVantgarde Bio, a clinical-stage biotechnology company based in Italy, has successfully raised $65,333,745 in its Series A funding round\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AAVantgarde Bio Raises $65 Million in Series A Funding.\" \/>\n<meta property=\"og:description\" content=\"Milan, Lombardy, Italy - AAVantgarde Bio, a clinical-stage biotechnology company based in Italy, has successfully raised $65,333,745 in its Series A funding round\" \/>\n<meta property=\"og:url\" content=\"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"Founder Lodge Latest News\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-08T20:22:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-08T20:22:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-90.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1507\" \/>\n\t<meta property=\"og:image:height\" content=\"625\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"ucheezuma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ucheezuma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/\"},\"author\":{\"name\":\"ucheezuma\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3\"},\"headline\":\"AAVantgarde Bio Raises $65 Million in Series A Funding.\",\"datePublished\":\"2023-06-08T20:22:48+00:00\",\"dateModified\":\"2023-06-08T20:22:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/\"},\"wordCount\":218,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\"},\"articleSection\":[\"Daily Startup Funding News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/\",\"name\":\"AAVantgarde Bio Raises $65 Million in Series A Funding.\",\"isPartOf\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#website\"},\"datePublished\":\"2023-06-08T20:22:48+00:00\",\"dateModified\":\"2023-06-08T20:22:50+00:00\",\"description\":\"Milan, Lombardy, Italy - AAVantgarde Bio, a clinical-stage biotechnology company based in Italy, has successfully raised $65,333,745 in its Series A funding round\",\"breadcrumb\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/founderlodge.com\/latest-news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AAVantgarde Bio Raises $65 Million in Series A Funding.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#website\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/\",\"name\":\"Founder Lodge Latest News\",\"description\":\"Get the latest updates on funding rounds and investment news for startups and businesses. Stay informed on capital raising trends and who&#039;s raising capital.\",\"publisher\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/founderlodge.com\/latest-news\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\",\"name\":\"Founder Lodge\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Founder Lodge\"},\"image\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3\",\"name\":\"ucheezuma\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g\",\"caption\":\"ucheezuma\"},\"url\":\"https:\/\/founderlodge.com\/latest-news\/author\/ucheezuma\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AAVantgarde Bio Raises $65 Million in Series A Funding.","description":"Milan, Lombardy, Italy - AAVantgarde Bio, a clinical-stage biotechnology company based in Italy, has successfully raised $65,333,745 in its Series A funding round","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/","og_locale":"en_US","og_type":"article","og_title":"AAVantgarde Bio Raises $65 Million in Series A Funding.","og_description":"Milan, Lombardy, Italy - AAVantgarde Bio, a clinical-stage biotechnology company based in Italy, has successfully raised $65,333,745 in its Series A funding round","og_url":"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/","og_site_name":"Founder Lodge Latest News","article_published_time":"2023-06-08T20:22:48+00:00","article_modified_time":"2023-06-08T20:22:50+00:00","og_image":[{"width":1507,"height":625,"url":"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/06\/image-90.png","type":"image\/png"}],"author":"ucheezuma","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ucheezuma","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/#article","isPartOf":{"@id":"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/"},"author":{"name":"ucheezuma","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3"},"headline":"AAVantgarde Bio Raises $65 Million in Series A Funding.","datePublished":"2023-06-08T20:22:48+00:00","dateModified":"2023-06-08T20:22:50+00:00","mainEntityOfPage":{"@id":"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/"},"wordCount":218,"commentCount":0,"publisher":{"@id":"https:\/\/founderlodge.com\/latest-news\/#organization"},"articleSection":["Daily Startup Funding News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/","url":"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/","name":"AAVantgarde Bio Raises $65 Million in Series A Funding.","isPartOf":{"@id":"https:\/\/founderlodge.com\/latest-news\/#website"},"datePublished":"2023-06-08T20:22:48+00:00","dateModified":"2023-06-08T20:22:50+00:00","description":"Milan, Lombardy, Italy - AAVantgarde Bio, a clinical-stage biotechnology company based in Italy, has successfully raised $65,333,745 in its Series A funding round","breadcrumb":{"@id":"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/founderlodge.com\/latest-news\/aavantgarde-bio-raises-65-million-in-series-a-funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/founderlodge.com\/latest-news\/"},{"@type":"ListItem","position":2,"name":"AAVantgarde Bio Raises $65 Million in Series A Funding."}]},{"@type":"WebSite","@id":"https:\/\/founderlodge.com\/latest-news\/#website","url":"https:\/\/founderlodge.com\/latest-news\/","name":"Founder Lodge Latest News","description":"Get the latest updates on funding rounds and investment news for startups and businesses. Stay informed on capital raising trends and who&#039;s raising capital.","publisher":{"@id":"https:\/\/founderlodge.com\/latest-news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/founderlodge.com\/latest-news\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/founderlodge.com\/latest-news\/#organization","name":"Founder Lodge","url":"https:\/\/founderlodge.com\/latest-news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Founder Lodge"},"image":{"@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3","name":"ucheezuma","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g","caption":"ucheezuma"},"url":"https:\/\/founderlodge.com\/latest-news\/author\/ucheezuma\/"}]}},"_links":{"self":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/6000"}],"collection":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/comments?post=6000"}],"version-history":[{"count":1,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/6000\/revisions"}],"predecessor-version":[{"id":6005,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/6000\/revisions\/6005"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/media\/6004"}],"wp:attachment":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/media?parent=6000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/categories?post=6000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/tags?post=6000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}